AbbVie's Rising Tide Masks Larger Industry Trends The recent upgrade of AbbVie Inc. 's stock by Evercore ISI has led some to hail it as one of the best long term investments.
However, a closer look reveals that beneath the surface lies a more nuanced story.
While AbbVie continues to dominate in the healthcare space with its blockbuster drugs SKYRIZI and RINVOQ, the company is facing challenges related to patent expirations and increasing competition from generic drugs.